INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
Rhea-AI Summary
INOVIO (NASDAQ: INO) reported Q1 2026 results and pipeline updates. R&D expenses were $14.1M, G&A $7.9M and total operating expenses $21.9M, all lower year over year. Net loss was $19.7M, or $0.28 per share. Cash and investments were $37.7M, excluding $16.0M April offering proceeds.
The FDA is actively reviewing the BLA for INO-3107 for recurrent respiratory papillomatosis, with an accelerated approval target PDUFA date of October 30, 2026. INOVIO plans U.S. self-commercialization and expects current cash to fund operations into Q1 2027. The company also announced an INO-5412 GBM trial collaboration with Akeso.
AI-generated analysis. Not financial advice.
Positive
- FDA BLA review for INO-3107 with October 30, 2026 PDUFA target
- Q1 2026 total operating expenses fell to $21.9M from $25.1M
- Q1 2026 R&D expenses decreased to $14.1M from $16.1M
- Q1 2026 G&A expenses decreased to $7.9M from $9.0M
- Net loss per share improved to $0.28 from $0.51 year over year
- Cash runway expected to extend into Q1 2027, beyond PDUFA date
- April 2026 equity offering added approximately $16.0M in net proceeds
- INO-5412 GBM Phase 2 trial collaboration and supply agreement with Akeso
Negative
- Q1 2026 net loss remained $19.7M year over year
- Cash, equivalents and short-term investments fell to $37.7M from $58.5M since December 31, 2025
- Estimated operational net cash burn of about $18M for Q2 2026
- Equity financing in April 2026 implies share dilution for existing holders
- FDA noted a potential review issue regarding INO-3107 accelerated approval eligibility
News Market Reaction – INO
On the day this news was published, INO gained 1.49%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -4.5% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $109.33M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INO’s move appears stock-specific. Only one tracked peer in momentum (PLX) is down modestly, while broader biotech peers in the list show mixed single‑digit moves up and down, with no clear sector-wide trend.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Q4/FY 2025 earnings | Positive | -1.2% | Reported 2025 results, BLA acceptance for INO-3107, and cost reductions. |
| Nov 10 | Q3 2025 earnings | Positive | -7.0% | Completed rolling BLA for INO-3107 and outlined confirmatory trial and runway. |
| Aug 12 | Q2 2025 earnings | Positive | +14.1% | Reduced net loss, lower R&D/G&A, public offering, and strong INO-3107 data. |
| May 13 | Q1 2025 earnings | Positive | -2.1% | Improved net loss, lower operating expenses, and progress toward INO-3107 BLA. |
| Mar 18 | Q4/FY 2024 earnings | Neutral | -6.7% | Full-year 2024 results with lower cash and losses, and BLA groundwork for INO-3107. |
Across the last five earnings-related releases, INO often delivered constructive pipeline and BLA progress updates, yet share reactions skewed slightly negative on average, indicating cautious market reception to fundamental news.
Over the last five earnings-related updates (Mar 2024–Mar 2026), INOVIO steadily advanced INO-3107 from planned BLA submission to full BLA acceptance with an FDA PDUFA target of Oct 30, 2026. Financially, the company has focused on lowering R&D and G&A expenses and narrowing net losses while repeatedly highlighting cash runway timelines. Earnings events frequently combined cost-control messages with regulatory and clinical milestones, but share-price reactions ranged from double‑digit gains to notable declines, reflecting mixed investor confidence despite pipeline progress.
Historical Comparison
In the past 12 months, INO’s five earnings updates averaged a -0.57% move, with markets often responding cautiously despite steady progress on INO-3107 and cost controls.
Earnings releases have tracked INO-3107’s evolution from planned BLA submission to full BLA acceptance with an FDA PDUFA date of October 30, 2026, alongside tightening operating expenses and updated cash runway guidance.
Market Pulse Summary
This announcement highlights Q1 2026 cost reductions, with R&D at $14.1 million and G&A at $7.9 million, and reiterates INO-3107’s FDA review with a October 30, 2026 PDUFA date. Management guides cash and investments of $37.7 million plus $16.0 million in April proceeds to fund operations into Q1 2027. Investors may focus on execution toward potential INO-3107 approval, the estimated $18 million Q2 2026 cash burn, and progress on partnered oncology and next‑generation DNA platforms.
Key Terms
biologics license application regulatory
accelerated approval program regulatory
pdufa regulatory
recurrent respiratory papillomatosis medical
glioblastoma medical
phase 2 adaptive platform trial medical
dna-encoded monoclonal antibody medical
bispecific antibody medical
AI-generated analysis. Not financial advice.
- Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the
U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 - Commercial readiness plans continue to advance in anticipation of a potential commercial launch for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis (RRP)
- Clinical trial collaboration and supply agreement announced with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of glioblastoma (GBM) in a Dana-Farber Cancer Institute-sponsored trial
- Current cash, cash equivalents, and short-term investments anticipated to fund operations into first quarter 2027, beyond the target PDUFA date
"We remain focused on advancing INO-3107 toward its target PDUFA date to ensure that every RRP patient has access to therapeutic options that work for them to reduce the need for surgery. We believe there remains a critical unmet need among patients diagnosed with this rare and devastating disease, and that INO-3107 has the potential to become the preferred product by patients and their physicians, if approved, based on clinical results, tolerability data and the simplicity of its patient-centric treatment regimen that does not require additional surgeries during the dosing window," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "While the BLA for INO-3107 is under active review, we continue to advance our commercial readiness plans in anticipation of a 2026 approval, as well as leverage the power of partnerships to advance other promising candidates in our pipeline."
Operational Highlights
INO-3107 – Recurrent Respiratory Papillomatosis (RRP)
INO-3107 is INOVIO's lead product candidate. It has been developed as a potential treatment for RRP, a rare and debilitating disease of the respiratory tract caused by infection with HPV-6 and/or HPV-11. In December 2025, the FDA accepted for review the company's BLA for INO-3107 under the accelerated approval program and set a target PDUFA date for October 30, 2026. Since then, the BLA has been under active review by the FDA, including the recent completion of the mid-cycle review meeting. INOVIO is focused on advancing INO-3107 through the regulatory process and working with the FDA as they complete their review of the BLA, including addressing the potential review issue they noted in their file acceptance letter regarding eligibility for review under the accelerated approval program. INOVIO continues to strongly believe that INO-3107 fulfills the criteria for accelerated approval by meeting a significant unmet need and providing a meaningful therapeutic benefit over existing treatments. As a part of communications about the mid-cycle review, the FDA has reiterated their intention to schedule the previously agreed to informal meeting to discuss their preliminary commentary on eligibility for review under the accelerated approval program.
INOVIO continues to engage with the RRP community, including presenting data from our Phase 1/2 trial of INO-3107 at the Combined Otolaryngology Spring Meeting (COSM), the premier educational and technology forum for the specialists who treat RRP. INOVIO will also be presenting at the upcoming American Society of Clinical Oncology (ASCO) Annual Conference.
In anticipation of a potential approval in 2026, INOVIO continues to advance commercial readiness plans, including incorporating key learnings from the launch of a competitor's recently approved RRP product. INOVIO believes INO-3107 has a positively differentiated product profile. INOVIO plans to commercialize INO-3107 itself in the
INO-5412
In March 2026, INOVIO announced a clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 (INO-5401 plus INO-9012 in a single vial) in combination with cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, for the potential treatment of glioblastoma (GBM). The combination therapy will be studied as a part of the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), a Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted by Mass General Brigham Cancer Care Inc. This novel combination builds on INOVIO's previous promising research in GBM and could potentially benefit patients by providing additional checkpoint inhibition through CTLA-4 binding.
Next-Generation DNA Medicine Candidates
INOVIO presented promising data from our next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several recent scientific conferences. Based on positive preclinical data on Factor VIII production for Hemophilia A, INOVIO is developing additional DPROT indications in the rare disease space, including Fabry disease and Hypophosphatasia (HPP), and is in discussions with potential partners to accelerate development of this promising platform.
General Corporate
INOVIO remains focused on financial discipline, directing resources to advance the INO-3107 program toward a potential 2026 approval and preparing for commercialization. The company strengthened its balance sheet with an underwritten public equity offering in April 2026. Net proceeds from the offering, after deducting underwriting discounts, commissions and offering expenses, were approximately
First Quarter 2026 Financial Results
- Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2026 decreased to
$14.1 million $16.1 million - General and Administrative (G&A) Expenses: G&A expenses decreased to
$7.9 million $9.0 million - Total Operating Expenses: Total operating expenses decreased to
$21.9 million $25.1 million - Net Loss: INOVIO's net loss for the three months ended March 31, 2026 was
$19.7 million $0.28 $19.7 million $0.51 - Cash, Cash Equivalents and Short-term Investments: As of March 31, 2026, cash, cash equivalents and short-term investments were
$37.7 million $16.0 million $58.5 million
Cash Guidance
INOVIO estimates that current cash, cash equivalents and short-term investments balances will support operations into the first quarter of 2027, beyond the target PDUFA date for INO-3107. This projection includes the net proceeds of
Conference Call / Webcast Information
INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including the timing and success of preclinical studies and clinical trials; the ability to obtain and maintain regulatory approval of our product candidates; the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026; a yet-to-be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program; the potential benefits of INO-3107 and our other potential product candidates, including our belief that INO-3107 has a positively differentiated product profile and the potential to become the preferred product by patients and their physicians, if approved; the clinical collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of GBM in the INSIGhT trial; the scope, progress and expansion of developing and commercializing our product candidates, including the anticipated commercial launch of INO-3107, if approved; our anticipated growth strategies; our ability to establish and maintain development partnerships; our estimated operational net cash burn of approximately
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
Inovio Pharmaceuticals, Inc. CONSOLIDATED BALANCE SHEETS | |||
March 31, | December 31, | ||
(Unaudited) | |||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | |||
Short-term investments | 11,409,607 | 14,239,145 | |
Prepaid expenses and other current assets, including from affiliated entity | 1,758,348 | 2,610,882 | |
Total current assets | 39,439,605 | 61,123,346 | |
Fixed assets, net | 2,210,759 | 2,527,603 | |
Investments in affiliated entity | — | 2,103,688 | |
Operating lease right-of-use assets | 6,114,303 | 6,542,923 | |
Other assets | 2,012,475 | 2,012,475 | |
Total assets | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Current liabilities: | |||
Accounts payable and accrued expenses | |||
Accounts payable and accrued expenses due to affiliated entity | — | 74,473 | |
Accrued clinical trial expenses | 817,331 | 650,680 | |
Common stock warrant liabilities | 24,929,459 | 29,067,162 | |
Operating lease liability | 2,908,820 | 2,822,622 | |
Total current liabilities | 37,923,025 | 43,668,555 | |
Operating lease liability, net of current portion | 5,786,235 | 6,545,204 | |
Total liabilities | 43,709,260 | 50,213,759 | |
Stockholders' equity: | |||
Preferred stock | — | — | |
Common stock | 69,773 | 68,997 | |
Additional paid-in capital | 1,841,482,163 | 1,839,830,405 | |
Accumulated deficit | (1,834,847,961) | (1,815,165,163) | |
Accumulated other comprehensive loss | (636,093) | (637,963) | |
Total Inovio Pharmaceuticals, Inc. stockholders' equity | 6,067,882 | 24,096,276 | |
Total liabilities and stockholders' equity | |||
Inovio Pharmaceuticals, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | |||
Three Months Ended March 31, | |||
2026 | 2025 | ||
Revenues: | |||
Revenue from collaborative arrangement | $— | ||
Operating expenses: | |||
Research and development | 14,070,107 | 16,090,902 | |
General and administrative | 7,879,886 | 9,024,970 | |
Total operating expenses | 21,949,993 | 25,115,872 | |
Loss from operations | (21,949,993) | (25,050,529) | |
Other income (expense): | |||
Interest income | 439,593 | 808,077 | |
Change in fair value of common stock warrant liabilities | 4,137,703 | 3,712,872 | |
(Loss) gain on investment in affiliated entity | (2,103,688) | 695,131 | |
Net unrealized gain on available-for-sale equity securities | 79,077 | 140,234 | |
Other expense, net | (285,490) | (482) | |
Net loss | |||
Net loss per share | |||
Basic and diluted | |||
Weighted average number of common shares used to compute net loss per share | |||
Basic and diluted | 69,101,910 | 38,613,653 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-first-quarter-2026-financial-results-and-recent-business-highlights-302771410.html
SOURCE INOVIO Pharmaceuticals, Inc.